Pfizer Signs $2.6 Billion CAR-T Deal with Starna Therapeutics
Pfizer has entered into an exclusive licensing agreement with China-based biotechnology company Starna Therapeutics to develop next-generation CAR-T therapies for autoimmune diseases. The deal is worth up to $2.6 billion, including an upfront payment and potential milestone payments.
Announced on November 18, 2026, the agreement gives Pfizer exclusive rights outside Greater China to develop, manufacture and commercialize three investigational in vivo chimeric antigen receptor T-cell (CAR-T) programs developed by Starna.
Under the agreement, Starna will receive an upfront payment of $330 million. The company is also eligible to receive up to $2.3 billion in additional payments linked to development and commercial milestones, along with royalties on net sales of approved products.
The partnership will also give Pfizer access to Starna’s proprietary in vivo CAR-T technology for use in inflammation and immunology, as well as oncology. Pfizer will have options to exclusively license additional compounds developed through a separate research collaboration and expand its rights into Greater China.
Unlike traditional CAR-T therapies, which involve collecting a patient’s immune cells, modifying them in a laboratory and returning them to the body, in vivo CAR-T treatments are designed to reprogram immune cells directly inside the patient’s body.
This approach could make CAR-T treatment simpler to develop and deliver by reducing the need for complex cell collection and manufacturing processes.
For autoimmune diseases, the technology aims to modify T cells so they can target and remove specific immune cells responsible for driving disease activity. This could offer a new treatment approach for patients whose conditions are not adequately controlled by existing therapies.
Starna is developing its in vivo CAR-T platform using RNA technology and a proprietary targeted lipid nanoparticle (LNP) delivery system. The technology is designed to deliver genetic instructions into selected cells, allowing them to produce CAR proteins and carry out targeted immune functions.
All three licensed programs are currently at the preclinical stage and have not yet entered human clinical trials.
Under the agreement, Pfizer will lead clinical development outside Greater China. The company also plans to manufacture the finished drug products for the initial clinical trials at its facilities in the United States. Pfizer will have exclusive commercial rights outside Greater China.
Michael Vincent, Chief Inflammation and Immunology Officer at Pfizer, said in vivo CAR-T represents a promising approach for treating autoimmune diseases, particularly for patients who have limited treatment options. He also highlighted Pfizer’s experience in RNA-based medicines as an important advantage in advancing the programs.
Rongkuan Hu, CEO of Starna Therapeutics, said the collaboration would help advance the company’s RNA medicines and targeted delivery technology toward potential treatments for patients worldwide.
The agreement strengthens Pfizer’s inflammation and immunology pipeline while expanding its presence in the growing in vivo CAR-T field. It also highlights increasing interest in applying cell therapy approaches beyond cancer, particularly for autoimmune diseases where more targeted treatment options are needed.
If successful in clinical development, these programs could open a new path for treating autoimmune conditions through direct immune cell reprogramming inside the body.
